^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

ARFIP2 (ADP Ribosylation Factor Interacting Protein 2)

i
Other names: ADP Ribosylation Factor Interacting Protein 2, POR1, Arfaptin-2, ADP-Ribosylation Factor-Interacting Protein 2, Partner Of RAC1 (Arfaptin 2), Partner Of RAC1, Protein POR1, Arfaptin 2, ARFIP2
Associations
Trials
1year
Identification of potential drug targets for four site-specific cancers by integrating human plasma proteome with genome. (PubMed, J Pharm Biomed Anal)
Causal proteins of breast and prostate cancer were expressed predominantly on macrophages in cancerous tissues. This study genetically identified several cancer causal proteins which provided new perspectives for the understanding of the etiology and development of novel targeted drugs for cancer.
Journal
|
CD36 (thrombospondin receptor) • TNFRSF9 (TNF Receptor Superfamily Member 9) • CASP8 (Caspase 8) • ARFIP2 (ADP Ribosylation Factor Interacting Protein 2)
almost2years
Combined transcriptome and proteome analysis reveals MSN and ARFIP2 as biomarkers for trastuzumab resistance of breast cancer. (PubMed, Breast Cancer Res Treat)
Our findings suggest that MSN and ARFIP2 could serve as promising biomarkers for predicting response to Tz, offering valuable insights for future research in the identification of diagnostic and therapeutic targets for BC patients with Tz resistance.
Journal • IO biomarker
|
ARFIP2 (ADP Ribosylation Factor Interacting Protein 2)
|
HER-2 positive
|
Herceptin (trastuzumab) • fulvestrant
2years
Deciphering the immunological and prognostic features of hepatocellular carcinoma through ADP-ribosylation-related genes analysis and identify potential therapeutic target ARFIP2. (PubMed, Cell Signal)
The ADPRI can be used to accurately predict the prognosis and immunotherapeutic response of hepatocellular carcinoma patients and providing valuable insights for future precision treatment of patients with hepatocellular carcinoma.
Journal • PARP Biomarker • IO biomarker
|
ARFIP2 (ADP Ribosylation Factor Interacting Protein 2)
3years
ARFIP2 Regulates EMT and Autophagy in Hepatocellular Carcinoma in Part Through the PI3K/Akt Signalling Pathway. (PubMed, J Hepatocell Carcinoma)
Our results substantiate a novel mechanism by which ARFIP2 can regulate the activity/phosphorylation of Akt to promote EMT and inhibit autophagy in part via the PI3K/Akt signalling pathway. The ARFIP2/PI3K/Akt axis may be a potential diagnostic biomarker and therapeutic target for HCC.
Journal
|
ARFIP2 (ADP Ribosylation Factor Interacting Protein 2)
over3years
Structuring and validating a prognostic model for low-grade gliomas based on the genes for plasma membrane tension. (PubMed, Front Neurol)
The results of IHC analysis confirmed that SH3GL2 protein expression was higher in patients with longer survival. Our plasma membrane tension-related gene prognostic signature is a prospective tool that can differentiate between prognosis, gene mutation landscape, immune microenvironment, immune infiltration and immunotherapeutic efficacy in LGG.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • ARFIP2 (ADP Ribosylation Factor Interacting Protein 2)
|
TP53 mutation • IDH1 mutation
over3years
Circular RNA circ_0021001 regulates miR-148b-3p/GREM1 axis to modulate proliferation and apoptosis of vascular smooth muscle cells. (PubMed, Metab Brain Dis)
Moreover, the downregulation of circ_0021001 could repress proliferation ability and induce apoptosis of HUASMCs. The mechanical analysis uncovered that circ_0021001 served as a sponge of miR-148b-3p to regulate GREM1 expression. Circ_0021001 silencing could suppress cell growth and induce apoptosis of HUASMCs partially through modulating the miR-148b-3p/GREM1, presented circ_0021001 as a promising therapeutic target for IA.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • PCNA (Proliferating cell nuclear antigen) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • ARFIP2 (ADP Ribosylation Factor Interacting Protein 2)
over4years
Effects of Salvia miltiorrhiza extract on lung adenocarcinoma. (PubMed, Exp Ther Med)
The data revealed that salvianolate not only suppressed lung adenocarcinoma tumor growth of in nude mice, but also downregulated the expression levels of ATP7A and ATP7B, which are important proteins in the tumorigenesis and chemotherapy of lung adenocarcinoma. The present study provided evidence for the potential use of Salvia miltiorrhiza extract for treating lung adenocarcinomas in the clinic.
Journal
|
ARFIP2 (ADP Ribosylation Factor Interacting Protein 2)